Investing.com - Fulcrum Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Fulcrum Therapeutics announced earnings per share of $-0.510 on revenue of $1.18M. Analysts polled by Investing.com EPS of $-0.650 on revenue of $2.65M.
Fulcrum Therapeutics 's are down 20% and is trading at $5.610 , still down 77.37% from its 52 week high of $24.79 set on Tuesday, April 5, 2022.
Fulcrum Therapeutics follows other major Healthcare sector earnings this month
Fulcrum Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar